Muhammed Mustafa Atci

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı. He is a member of the American Society of Clinical Oncology (ASCO). He joined this organization in 2018. Dr. Atci treats cancers using immunotherapy, targeted therapy, and chemotherapy protocols.

Oncology Specialization and Treatment Approach

Dr. Atci treats malignancies including lung, breast, pancreatic, and colorectal cancers. He also treats sarcomas and medullary thyroid cancer. The doctor uses diagnostic tools such as PET/CT and Ga-68 DOTA-TATE PET/CT imaging. This imaging helps detect neuroendocrine tumors using radioactive tracers. Dr. Atci applies targeted therapy for lung cancer patients. He also performs Hyperthermic Intraperitoneal Chemotherapy (HIPEC). This technique delivers heated chemotherapy directly into the abdomen during surgery. His research includes using the De Ritis ratio. This ratio helps him predict lung metastasis in testicular cancer patients.

Work Experience

• 2025 – Present — Associate Professor of Medical Oncology, İstinye University, Liv Hospital Topkapı, Turkey
• 2023 – 2025 — Associate Professor and Education Coordinator, Prof. Dr. Cemil Taşcıoğlu City Hospital, Turkey
• 2018 – 2021 — Medical Oncologist, Prof. Dr. Cemil Taşcıoğlu City Health Application and Research Center, Turkey
• 2017 – 2018 — Internal Medicine Specialist, Istanbul Haseki Training and Research Hospital, Turkey
• 2015 – 2017 — Internal Medicine Specialist, Tokat State Hospital, Turkey

Education and Training

• 2003 – 2009 — Istanbul University – Cerrahpaşa Faculty of Medicine, Turkey
• 2011 – 2015 — Residency in Internal Medicine, University of Health Sciences – Istanbul Şişli Hamidiye Etfal Center, Turkey

Scientific Research and Publications

Dr. Atci has published 19 peer-reviewed international papers. His work focuses on prognostic biomarkers and survival outcomes. Furthermore, he researches factors affecting survival in retroperitoneal sarcomas and esophageal squamous cell carcinoma. Notable publications include:

• "The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients" – Journal of Chemotherapy
• "A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio" – Current Urology
• "Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response?" – Expert Review of Anticancer Therapy
• "The prognostic value of postoperative lymph node ratio in neoadjuvant-treated gastric adenocarcinoma patients" – Cureus
• "The predictive role of metabolic tumor volume on non-response to neoadjuvant chemotherapy in breast cancer" – Journal of Oncology Pharmacy Practice

Professional Memberships

• American Society of Clinical Oncology (ASCO)
• Turkish Society of Medical Oncology